

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

A Convenient Synthesis of Novel Phosphoramidate Mustard Analogues of 2-Arylquinolone

Jinwei Yuan^a; Xiaolan Chen^a; Lingbo Qu^{ab}; Shouren Zhang^a; Jiansha Lu^a; Yufen Zhao^{ac}

^a Key Laboratory of Organic Chemistry and Chemical Biology, Henan Province, Department of Chemistry, Zhengzhou University, Zhengzhou, P. R. China ^b Henan University of Technology, Henan Province, Zhengzhou, P. R. China ^c Key Laboratory for Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, School of Life Sciences and Engineering, Tsinghua University, Beijing, P. R. China

To cite this Article Yuan, Jinwei , Chen, Xiaolan , Qu, Lingbo , Zhang, Shouren , Lu, Jiansha and Zhao, Yufen(2009) 'A Convenient Synthesis of Novel Phosphoramidate Mustard Analogues of 2-Arylquinolone', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 184: 11, 2936 — 2944

To link to this Article: DOI: 10.1080/10426500802625529

URL: <http://dx.doi.org/10.1080/10426500802625529>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

A Convenient Synthesis of Novel Phosphoramidate Mustard Analogues of 2-Arylquinolone

Jinwei Yuan,¹ Xiaolan Chen,¹ Lingbo Qu,^{1,2}
Shouren Zhang,¹ Jiansha Lu,¹ and Yufen Zhao^{1,3}

¹Key Laboratory of Organic Chemistry and Chemical Biology, Henan Province, Department of Chemistry, Zhengzhou University, Zhengzhou, P. R. China

²Henan University of Technology, Henan Province, Zhengzhou, P. R. China

³Key Laboratory for Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, School of Life Sciences and Engineering, Tsinghua University, Beijing, P. R. China

A series of novel phosphoramidate mustard analogues of 2-arylquinolones are synthesized through a convenient and facile phosphorylated reaction, and their structures are elucidated by NMR, IR, and HR MS. The amino acid esters and phosphoryl nitrogen mustard are linked to 2-arylquinolone to improve their undesirable physicochemical and biological properties.

Keywords Amino acid ester; 2-arylquinolone; phosphoramidate mustard

INTRODUCTION

2-Arylquinolones are a class of molecules used as aza analogues of flavones (Figure 1). Over the last 10 years, 2-arylquinolones and related compounds have been the subject of extensive studies as potent cytotoxic antimitotic agents,^{1,2} antibacterial agents, anti-platelet agents, and as cardiovascular protectors.^{3,4,5} Moreover, 2-arylquinolones have been the subject of investigations as a new class of antitumor agents. With the goal of enhancing their pharmacological and biological activity, several 2-arylquinolone derivatives have been synthesized previously, and their biological activities have also been studied.^{6,7,8,9}

Glyciphosphoramidate, *N,N*-bis(chloroethyl)-*N',N'*-bis-(carbethoxymethyl)phosphoric triamide (Figure 2) is a synthetic anticancer agent

Received 12 September 2008; accepted 13 November 2008.

Address correspondence to Xiaolan Chen and Yufen Zhao, Department of Chemistry, Zhengzhou University, 75 Daxue Road, Henan Province, Zhengzhou 450052, P.R. China. E-mail: chenxl@zzu.edu.cn




FIGURE 1 X = O: flavone; X = N: 2-phenyl-4-quinolone.

used against a broad spectrum of tumor in animal tests and has been undergoing evaluation in China for some time. Glyciphosphoramidate is activated in the presence of plasma or serum. This unique property of glyciphosphoramidate makes the compound a useful agent for topical use in the treatment of cancerous ulceration and malignant tumors.¹⁰⁻¹² Within the pharmaceutical industry, several candidates belonging to this structural class have been synthesized as potential antitumor agents.^{13,14} In the hope of increasing the biological specificity of these compounds, the phosphoramidate mustard group has been linked to various carrier molecules such as carbohydrates.^{15,16}

Our interest was in synthesizing a series of amino acid esters and phosphoryl nitrogen mustard linked 2-arylquinolone derivatives to improve their undesirable physicochemical and biological properties as potential antitumor agents. In the work described in this article, novel phosphoramidate mustard analogues of 2-arylquinolone **4a-g** are synthesized through a convenient and facile phosphorylated reaction (Scheme 1). The structures of compounds **4a-g** have been elucidated by NMR, IR, and HR MS for the first time.





FIGURE 2 Glyciphosphoramidate.

a: $\text{R}_1 = \text{CH}_3$, $\text{R}_2 = \text{H}$, $\text{R}_3 = \text{H}$;b: $\text{R}_1 = \text{CH}_3$, $\text{R}_2 = \text{CH}_3$, $\text{R}_3 = \text{H}$;c: $\text{R}_1 = \text{C}_2\text{H}_5$, $\text{R}_2 = \text{CH}_3$, $\text{R}_3 = \text{H}$;d: $\text{R}_1 = \text{CH}_3$, $\text{R}_2 = \text{H}$, $\text{R}_3 = \text{Cl}$;e: $\text{R}_1 = \text{CH}_3$, $\text{R}_2 = \text{H}$, $\text{R}_3 = \text{OCH}_3$;f: $\text{R}_1 = \text{CH}_3$, $\text{R}_2 = \text{H}$, $\text{R}_3 = \text{CH}_3$;g: $\text{R}_1 = \text{C}_2\text{H}_5$, $\text{R}_2 = \text{H}$, $\text{R}_3 = \text{CH}_3$ **SCHEME 1** Synthesis of phosphoramidate mustard analogues of 2-arylquinolone **4a-g**.

RESULTS AND DISCUSSION

In the synthesis of phosphoramidate mustard analogues of 2-arylquinolone (**4**) (Scheme 1), bis-(β -chloroethyl)-amine hydrochloride was first reacted with phosphorus oxychloride at reflux temperature to give di-(2-chloroethyl)-phosphoramidic dichloride (**1**). Then it was coupled with different *L*-amino acid esters hydrochloride salts at low temperature to achieve *N,N*-bis(2-chloroethyl) phosphonamidic chlorides (**2**), which were not purified further by the chromatography. 2-Arylquinolone (**3**) was reacted with *N,N*-bis(2-chloroethyl) phosphonamidic chloride (**2**) in THF by a convenient and facile phosphorylation reaction to form phosphoramidate mustard analogues of 2-arylquinolone (**4**) in the presence of triethylamine at low temperatures. The yields of the final purified compounds were in the range 30–49%. The structures of all the newly synthesized 2-arylquinolone derivatives were confirmed by NMR, IR, and HR MS.

2-Arylquinolones can be synthesized by several pathways.^{2,3} The degree of unsaturation in the C-ring causes it to exist in tautomeric equilibriums, 2-arylquinolone and 2-aryl-4-hydroquinoline isomer. 2-Arylquinolones are found to exist exclusively in solution phase and solid state.¹⁷ The experimental results show that the final product is compound (**4**). This conclusion was confirmed by ¹³C NMR. For example, ¹³C NMR of compound **4a** showed 3-C at δ 109.01 ($^3J_{\text{P-C}} = 2.83$ Hz), 4-C at δ 154.82 ($^2J_{\text{P-C}} = 7.38$ Hz), and 10-C at δ 108.57 ($^3J_{\text{P-C}} = 5.00$ Hz) were split into doublet, respectively. The reason is because the phosphorus atom makes the surrounding carbon atoms split. We speculate that 2-arylquinolone (**3**) first undergoes a tautomeric change to become 2-aryl-4-hydroquinoline (**3'**), and then reacts with *N,N*-bis(2-chloroethyl) phosphonamidic chloride (**2**) to obtain the final product (**4**).

NMR spectra of **4a**, **4d**, **4e**, **4f**, and **4g** show only a group of signals because these compounds are formed by a pair of enantiomers, respectively. However, two groups of signals could be found from NMR spectra of **4b** and **4c**. The reason is due to the chirality at the phosphorus center and *L*-amino acid esters. Each of compound **4b** and **4c** includes two isomers (Sp and Rp), and the confirmation of the presence of two isomers is shown by ³¹P NMR. Separation of the diastereoisomers by column chromatography has been difficult and problematic. By using ³¹P NMR, we were able to approximately determine the ratios of each isomer. It is interesting to note that in the case of the *L*-alanine methylester isomer (**4b** and **4c**), a ratio of approximately 20% of isomer | and 80% isomer || can be obtained. This indicates that the approach of 2-arylquinolone in the final segment of the synthesis is affected by the configuration at the amino acid terminal of the phosphorochloridate.

In summary, novel phosphoramidate mustard analogues of 2-arylquinolone **4a-g** have been synthesized through a versatile method. Work is in progress in our laboratory to further evaluate the biological activity of these analogues as potential antitumor prodrugs.

EXPERIMENTAL

All experiments involving water-sensitive compounds were conducted under scrupulously dry conditions. The solvents were dried by appropriate methods.¹⁸ IR spectra were recorded on a Shimadzu IR-408. ¹H, ¹³C, and ³¹P NMR spectra were recorded on a Bruker Avance DPX spectrometer operating at 400.13, 100.61, and 161.98 MHz, respectively, with ¹³C and ³¹P spectra being recorded as proton-decoupled. All NMR spectra were recorded in CDCl₃ at room temperature (20°C ± 3°C). ¹H

and ^{13}C chemical shifts are quoted in parts per million downfield from TMS. ^{31}P chemical shifts are quoted in parts per million relative to an external 85% H_3PO_4 standard. J values refer to coupling constants, and signal splitting patterns are described as singlet (s), broad singlet (bs), doublet (d), triplet (t), quartet (q), multiplet (m), or combinations thereof. TLC was performed on silica gel plates and preparative chromatograph on columns of silica gel (200–300 mesh). TOF MS were recorded on Q-Tof Micro.

Di-(2-chloroethyl)-phosphoramidic Dichloride (1)

A suspension of bis-(β -chloroethyl)-amine hydrochloride (40 g, 0.23 mol) in distilled phosphorus oxychloride (174 mL, 1.78 mol, b.p. 105.5–107.5°C) was refluxed for 24 h until complete solution resulted. The excess phosphorus oxychloride was removed by distillation, and the residue was crystallized from acetone-petroleum ether, yielding the desired product, mp 55–57°C.¹⁹

General Procedure to Prepare *N,N*-Bis(2-chloroethyl) Phosphonamidic Chloride (2a–g)

Di-(2-chloroethyl)-phosphoramidic dichloride (5 g, 19.5 mmol) and the appropriate *L*-amino acid ester hydrochloric salt (19.5 mmol) were suspended in anhydrous dichloromethane. Anhydrous triethylamine (2.7 mL, 19.5 mmol) was added dropwise at -78°C , and after 2 h, the reaction was left to warm to room temperature. The formation of *N,N*-bis(2-chloroethyl) phosphonamidic chloride was monitored by ^{31}P NMR. After 6–15 h, the solvent was removed under reduced pressure, and the solid obtained was washed with anhydrous ether (2×20 mL), filtered, and the filtrate was concentrated to dryness to give the crude products (**2**), which were used without further purification.

General Procedure to Prepare Phosphoramide Mustard Analogues of 2-Arylquinolone (4a–g)

A solution of 2-arylquinolone (1.8 mmol) and the appropriate *N,N*-bis(2-chloroethyl) phosphonamidic chloride (**2**) (2.0–3.0 mol) in anhydrous tetrahydrofuran was stirred at -40°C for 30 min, and anhydrous triethylamine (0.3 mL, 2.0 mmol) was added dropwise to the solution over a period of 30 min. After 1 h, the reaction was left to warm to room temperature and stirred for a further 10–24 h. The solution was filtered, and the filtrate was evaporated to dryness to give the residues

as yellow oils. The residues were purified by column chromatography on silica gel (cyclohexane:ethyl acetate, 3:1).

Compound 4a ($C_{24}H_{28}Cl_2N_3O_6P$)

Mp: 165–166°C, Yield: 49%. HR MS 556.1170 $[M + H]^+$ (calculated for $C_{24}H_{28}Cl_2N_3O_6PH$ 556.1171); IR(KBr) $\nu(\text{cm}^{-1})$: 3408 (N-H), 2926, 2854 ($-\text{CH}_3$, $-\text{CH}_2$), 1748 (C = O), 1619 (heterocycle), 1584 (C = N), 1374 (P = O), 1212 (P-O-Ar), 772 (C-Cl); ^1H NMR(CDCl_3) δ : 7.77 (d, 1H, $^4J_{\text{P-H}} = 1.68$ Hz, 3-H), 6.59 (d, 1H, $^4J_{\text{H-H}} = 2.24$ Hz, 6-H), 7.16 (d, 1H, $^4J_{\text{H-H}} = 2.08$ Hz, 8-H), 8.12 (d, 2H, $^3J_{\text{H-H}} = 8.12$ Hz, 2'6'-H), 7.47 (m, 3H, 3'4'5'-H), 4.08 (s, 3H, 5-OCH₃), 4.03 (s, 3H, 7-OCH₃), 3.73 (m, 8H, NCH₂CH₂Cl), 3.70 (s, 3H, OCH₃); ^{13}C NMR(CDCl_3) δ : 158.94 (2-C), 109.01 (d, $^3J_{\text{P-C}} = 2.83$ Hz, 3-C), 154.82 (d, $^2J_{\text{P-C}} = 7.38$ Hz, 4-C), 155.73 (5-C), 99.70 (6-C), 161.19 (7-C), 101.38 (8-C), 153.52 (9-C), 108.57 (d, $^3J_{\text{P-C}} = 5.00$ Hz, 10-C), 138.64 (C-1'), 128.73 (2'6'-C), 127.55 (3'5'-C), 129.64 (4'-C), 55.68 (5-OCH₃), 56.28 (7-OCH₃), 49.21 (d, $^2J_{\text{P-C}} = 4.57$ Hz, NCH₂), 42.24 (CH₂Cl), 42.06 (d, $^2J_{\text{P-C}} = 3.42$ Hz, $-\text{CH}_2$), 171.37 (d, $^3J_{\text{P-C}} = 9.40$ Hz, C = O), 52.43 (OCH₃); ^{31}P NMR(CDCl_3) δ : 11.00.

Compound 4b ($C_{25}H_{30}Cl_2N_3O_6P$)

Mp: 155–157°C, Yield: 36%. HR MS 570.1320 $[M + H]^+$ (calculated for $C_{25}H_{30}Cl_2N_3O_6PH$ 570.1328); IR(KBr) $\nu(\text{cm}^{-1})$: 2929, 2851 ($-\text{CH}_3$, $-\text{CH}_2$), 1743 (C = O) 1636(heterocycle), 1609 (C = N), 1374 (P = O), 1213 (P-O-Ar), 772 (C-Cl); ^1H NMR(CDCl_3) δ : 7.81, 7.79 (d, 1H, $^4J_{\text{P-H}} = 1.56$ Hz, 3-H), 6.60, 6.59 (d, 1H, $^4J_{\text{H-H}} = 2.24$ Hz, 6-H), 7.17, 7.16 (d, 1H, $^4J_{\text{H-H}} = 2.04$ Hz, 8-H), 8.14, 8.11 (d, 2H, $^3J_{\text{H-H}} = 8.36$ Hz, 2'6'-H), 7.47, 7.47 (m, 3H, 3'4'5'-H), 4.07, 4.03 (s, 3H, 5-OCH₃), 3.96, 3.96 (s, 3H, 7-OCH₃), 3.68, 3.52 (m, 8H, NCH₂CH₂Cl), 4.10, 4.10 (m, 1H, $-\text{CH}$), 1.44, 1.26 (d, 3H, $^4J_{\text{P-H}} = 6.72$ Hz, $-\text{CH}_3$), 3.74, 3.60 (s, 3H, OCH₃); ^{13}C NMR(CDCl_3) δ : 158.94, 158.86 (2-C), 108.65, 108.57 (d, $^3J_{\text{P-C}} = 2.78$ Hz, 3-C), 154.92, 154.85 (d, $^2J_{\text{P-C}} = 6.91$ Hz, 4-C), 155.93, 155.73 (5-C), 99.68, 99.60 (6-C), 161.22, 161.19 (7-C), 101.38, 101.26 (8-C), 153.49, 153.49 (9-C), 109.17, 109.14 (d, $^3J_{\text{P-C}} = 3.03$ Hz, 10-C), 138.67, 138.63 (C-1'), 128.75, 128.75 (2'6'-C), 127.54, 127.54 (3'5'-C), 129.66, 129.63 (4'-C), 56.33, 56.15 (5-OCH₃), 55.71, 55.68 (7-OCH₃), 49.49, 49.17 (d, $^2J_{\text{P-C}} = 4.56$ Hz, NCH₂), 42.20, 42.20 (CH₂Cl), 49.74, 49.71 (d, $^2J_{\text{P-C}} = 3.20$ Hz, $-\text{CH}$), 21.57, 20.83 (d, $^3J_{\text{P-C}} = 3.72$ Hz, $-\text{CH}_3$), 174.49, 174.05 (d, $^3J_{\text{P-C}} = 8.58$ Hz, C = O), 52.57, 52.48 (OCH₃); ^{31}P NMR(CDCl_3) δ : 9.76, 9.56.

Compound 4c ($C_{26}H_{32}Cl_2N_3O_6P$)

Mp: 167–169°C, Yield: 40%. HR MS 584.1480 $[M + H]^+$ (calculated for $C_{26}H_{32}Cl_2N_3O_6PH$ 584.1484); IR(KBr) $\nu(\text{cm}^{-1})$: 3399 (N-H), 2930,

2852 (-CH₃, -CH₂), 1740 (C = O), 1626 (heterocycle), 1285 (P = O), 1213 (P-O-Ar), 776 (C-Cl); ¹H NMR(CDCl₃) δ: 7.82, 7.79 (d, 1H, ⁴J_{P-H} = 1.48 Hz, 3-H), 6.60, 6.58 (d, 1H, J = 2.16 Hz, 6-H), 7.17, 7.16 (d, 1H, ⁴J_{H-H} = 1.96 Hz, 8-H), 8.14, 8.12 (d, 2H, ⁴J_{H-H} = 8.00 Hz, 2'6'-H), 7.47, 7.47 (m, 3H, 3'4'5'-H), 4.07, 4.03 (s, 3H, 5-OCH₃), 3.96, 3.96 (s, 3H, 7-OCH₃), 3.60, 3.60 (m, 8H, NCH₂CH₂Cl), 4.05, 4.05 (m, 1H, -CH), 1.44, 1.28 (d, 3H, ³J_{H-H} = 6.88 Hz, -CH₃), 4.18, 4.18 (q, 2H, ³J_{H-H} = 7.36 Hz, OOCCH₂), 1.26, 1.15 (t, 3H, ³J_{H-H} = 7.16 Hz, OOCCH₃); ¹³C NMR(CDCl₃) δ: 158.94, 158.87 (2-C), 108.68, 108.64 (d, ³J_{P-C} = 3.56 Hz, 3-C), 154.94, 154.87 (d, ²J_{P-C} = 7.13 Hz, 4-C), 155.93, 155.76 (5-C), 99.66, 99.58 (6-C), 161.21, 161.18 (7-C), 101.37, 101.25 (8-C), 153.50, 153.50 (9-C), 109.17, 109.13 (d, ³J_{P-C} = 3.09 Hz, 10-C), 138.67, 138.65 (C-1'), 128.75, 128.75 (2'6'-C), 127.54, 127.54 (3'5'-C), 129.65, 129.61 (4'-C), 56.34, 56.14 (5-OCH₃), 55.71, 55.68 (7-OCH₃), 49.51, 49.20 (d, ²J_{P-C} = 4.49 Hz, NCH₂), 42.21, 42.21 (CH₂Cl), 49.77, 49.74 (d, ²J_{P-C} = 3.32 Hz, -CH), 21.63, 20.88 (d, ³J_{P-C} = 3.52 Hz, -CH₃), 174.03, 173.57 (d, ³J_{P-C} = 8.84 Hz, C = O), 61.65, 61.57 (OOCCH₂), 14.16, 14.00 (OOCCH₃); ³¹P NMR(CDCl₃) δ: 9.81, 9.58.

Compound 4d (C₂₄H₂₇Cl₃N₃O₆P)

Mp: 80–81°C, Yield: 30%. HR MS 590.0780 [M + H]⁺ (calculated for C₂₄H₂₇Cl₃N₃O₆PH 590.0781); IR(KBr) ν(cm⁻¹): 3411 (N-H), 2954, 2926, 2854 (-CH₃, -CH₂), 1748 (C = O), 1619 (heterocycle), 1577 (C = N), 1279 (P = O), 1211 (P-O-Ar), 752 (C-Cl); ¹H NMR(CDCl₃) δ: 7.74 (d, 1H, ⁴J_{P-H} = 1.52 Hz, 3-H), 6.60 (d, 1H, ⁴J_{H-H} = 2.24 Hz, 6-H), 7.13 (d, 1H, ⁴J_{H-H} = 2.20 Hz, 8-H), 8.08 (d, 2H, ³J_{H-H} = 8.68 Hz, 2'6'-H), 7.44 (d, 2H, ³J_{H-H} = 8.60 Hz, 3'5'-H), 4.08 (s, 3H, 5-OCH₃), 3.96 (s, 3H, 7-OCH₃), 3.71 (m, 8H, NCH₂CH₂Cl), 3.52 (m, 2H, -CH₂), 3.71 (s, 3H, OOCCH₃); ¹³C NMR(CDCl₃) δ: 157.60 (2-C), 108.63 (d, ³J_{P-C} = 2.88 Hz, 3-C), 155.00 (d, ²J_{P-C} = 7.11 Hz, 4-C), 155.74 (5-C), 99.91 (6-C), 161.35 (7-C), 101.34 (8-C), 153.52 (9-C), 108.72 (d, ³J_{P-C} = 3.62 Hz, 10-C), 137.08 (C-1'), 128.84 (2'6'-C), 128.92 (3'5'-C), 135.85 (4'-C), 55.72 (5-OCH₃), 56.34 (7-OCH₃), 49.20 (d, ²J_{P-C} = 4.59 Hz, NCH₂), 42.23 (CH₂Cl), 42.05 (d, ²J_{P-C} = 3.44 Hz, -CH₂), 171.38 (d, ³J_{P-C} = 9.40 Hz, C = O), 52.48 (OOCCH₃); ³¹P NMR(CDCl₃) δ: 11.05.

Compound 4e (C₂₅H₃₀Cl₂N₃O₇P)

Mp: 105–106°C, Yield: 39%. HR MS 586.1272 [M + H]⁺ (calculated for C₂₅H₃₀Cl₂N₃O₇PH 586.1277); IR(KBr) ν(cm⁻¹): 3422 (N-H), 2958, 2926, 2853 (-CH₃, -CH₂), 1747 (C = O), 1616 (heterocycle), 1375 (P = O), 1212 (P-O-Ar), 832 (C-Cl); ¹H NMR(CDCl₃) δ: 7.72 (d, 1H, ⁴J_{P-H} = 1.52 Hz, 3-H), 6.56 (d, 1H, ⁴J_{H-H} = 2.20 Hz, 6-H), 7.13 (d, 1H, ⁴J_{H-H} =

2.08 Hz, 8-H), 8.10 (d, 2H, $^3J_{\text{H-H}} = 8.84$ Hz, 2'6'-H), 7.00 (d, 2H, $^3J_{\text{H-H}} = 8.88$ Hz, 3'5'-H), 4.05 (s, 3H, 5-OCH₃), 3.95 (s, 3H, 7-OCH₃), 3.87 (s, 3H, 4'-OCH₃), 3.72 (m, 8H, NCH₂CH₂Cl), 3.51 (m, 2H, -CH₂), 3.72 (s, 3H, OOCH₃); ^{13}C NMR(CDCl₃) δ : 158.49 (2-C), 108.45 (d, $^3J_{\text{P-C}} = 2.78$ Hz, 3-C), 154.70 (d, $^2J_{\text{P-C}} = 7.35$ Hz, 4-C), 155.74 (5-C), 99.37 (6-C), 161.16 (7-C), 101.24 (8-C), 153.50 (9-C), 108.22 (d, $^3J_{\text{P-C}} = 4.87$ Hz, 10-C), 128.84 (C-1'), 128.95 (2'6'-C), 114.09 (3'5'-C), 161.07 (4'-C), 55.39 (5-OCH₃), 56.27 (7-OCH₃), 55.68 (4'-OCH₃), 49.22 (d, $^2J_{\text{P-C}} = 4.56$ Hz, NCH₂), 42.25 (CH₂Cl), 42.07 (d, $^2J_{\text{P-C}} = 3.35$ Hz, -CH₂), 171.40 (d, $^3J_{\text{P-C}} = 9.28$ Hz, C = O), 52.44 (OOCH₃); ^{31}P NMR(CDCl₃) δ : 11.00.

Compound 4f (C₂₅H₃₀Cl₂N₃O₆P)

Mp: 77–78°C, Yield: 36%. HR MS 570.1322 [M + H]⁺ (calculated for C₂₅H₃₀Cl₂N₃O₆PH 570.1328); IR(KBr) $\nu(\text{cm}^{-1})$: 3442 (N-H), 2927, 2856 (-CH₃, -CH₂), 1744 (C = O), 1634 (heterocycle), 1374 (P = O), 1212 (P-O-Ar), 771 (C-Cl); ^1H NMR(CDCl₃) δ : 7.73 (d, 1H, $^4J_{\text{P-H}} = 1.68$ Hz, 3-H), 6.58 (d, 1H, $^4J_{\text{H-H}} = 2.28$ Hz, 6-H), 7.13 (d, 1H, $^4J_{\text{H-H}} = 2.28$ Hz, 8-H), 8.01 (d, 2H, $^3J_{\text{H-H}} = 8.20$ Hz, 2'6'-H), 7.27 (d, 2H, $^3J_{\text{H-H}} = 8.00$ Hz, 3'5'-H), 4.06 (s, 3H, 5-OCH₃), 3.96 (s, 3H, 7-OCH₃), 2.41 (s, 3H, 4'-CH₃), 3.75 (m, 8H, NCH₂CH₂Cl), 3.51 (m, 2H, -CH₂), 3.75 (s, 3H, OOCH₃); ^{13}C NMR(CDCl₃) δ : 158.96 (2-C), 108.79 (d, $^3J_{\text{P-C}} = 2.90$ Hz, 3-C), 154.67 (d, $^2J_{\text{P-C}} = 8.18$ Hz, 4-C), 155.71 (5-C), 99.54 (6-C), 161.13 (7-C), 101.41 (8-C), 153.58 (9-C), 108.45 (d, $^3J_{\text{P-C}} = 4.97$ Hz, 10-C), 135.83 (C-1'), 127.40 (2'6'-C), 129.46 (3'5'-C), 139.79 (4'-C), 55.69 (5-OCH₃), 56.28 (7-OCH₃), 21.36 (4'-CH₃), 49.24 (d, $^2J_{\text{P-C}} = 4.50$ Hz, NCH₂), 42.24 (CH₂Cl), 42.07 (d, $^2J_{\text{P-C}} = 3.33$ Hz, -CH₂), 171.39 (d, $^3J_{\text{P-C}} = 9.28$ Hz, C = O), 52.45 (OOCH₃); ^{31}P NMR(CDCl₃) δ : 10.93.

Compound 4g (C₂₆H₃₂Cl₂N₃O₆P)

Mp: 85–86°C, Yield: 32%. HR MS 584.1485 [M + H]⁺ (calculated for C₂₆H₃₂Cl₂N₃O₆PH 584.1484); IR(KBr) $\nu(\text{cm}^{-1})$: 3402 (N-H), 2925, 2848 (-CH₃, -CH₂), 1744 (C = O), 1619 (heterocycle), 1591 (C = N), 1350 (P = O), 1210 (P-O-Ar), 829 (C-Cl); ^1H NMR(CDCl₃) δ : 7.75 (d, 1H, $^4J_{\text{P-H}} = 1.52$ Hz, 3-H), 6.58 (d, 1H, $^4J_{\text{H-H}} = 2.16$ Hz, 6-H), 7.14 (d, 1H, $^4J_{\text{H-H}} = 2.16$ Hz, 8-H), 8.02 (d, 2H, $^3J_{\text{H-H}} = 8.16$ Hz, 2'6'-H), 7.28 (d, 2H, $^3J_{\text{H-H}} = 8.16$ Hz, 3'5'-H), 4.06 (s, 3H, 5-OCH₃), 3.96 (s, 3H, 7-OCH₃), 2.41 (s, 3H, 4'-CH₃), 3.71 (m, 8H, NCH₂CH₂Cl), 3.51 (m, 2H, -CH₂), 4.18 (q, 2H, $^3J_{\text{H-H}} = 2.12$ Hz, OOCCH₃), 1.25 (t, 3H, $^3J_{\text{H-H}} = 2.36$ Hz, -OOCCH₃); ^{13}C NMR(CDCl₃) δ : 158.96 (2-C), 108.82 (d, $^3J_{\text{P-C}} = 3.02$ Hz, 3-C), 154.73 (d, $^2J_{\text{P-C}} = 7.35$ Hz, 4-C), 155.74 (5-C), 99.52 (6-C), 161.12 (7-C), 101.39 (8-C), 153.58 (9-C), 108.48 (d, $^3J_{\text{P-C}} = 5.07$ Hz, 10-C), 135.87 (C-1'), 127.42 (2'6'-C), 129.46 (3'5'-C), 139.77 (4'-C), 55.69 (5-OCH₃), 56.29 (7-OCH₃),

49.28 (d, $^2J_{\text{P-C}} = 4.75$ Hz, NCH_2), 42.27 (CH_2Cl), 42.21 (d, $^2J_{\text{P-C}} = 3.05$ Hz, $-\text{CH}_2$), 170.96 (d, $^3J_{\text{P-C}} = 9.69$ Hz, $\text{C} = \text{O}$), 61.65 (OOCH_2), 14.14 ($-\text{OOCCH}_3$); ^{31}P NMR(CDCl_3) δ : 10.97.

REFERENCES

- [1] L. Li, H. K. Wang, S. C. Kuo, T. S. Wu, R. A. Mauge, and C. M. Lin, *J. Med. Chem.*, **37**(20), 3400–3407 (1994).
- [2] M. Hadjeri, A. M. Mariotte, and A. Boumendjel, *Chem. Pharm. Bull.*, **49**(10), 1352–1355 (2001).
- [3] C. Beney, M. Hadjeri, A. M. Mariotte, and A. Boumendjel, *Tetrahedron Lett.*, **41**, 7037–7039 (2000).
- [4] M. Hadjeri, E. L. Peiller, C. Beney, N. Deka, M. A. Lawson, C. Dumontet, and A. Boumendjel, *J. Med. Chem.*, **47**(20), 4964–4970 (2004).
- [5] C. Pain, S. Célanière, G. Guillaumet, and B. Joseph, *Tetrahedron*, **59**(48), 9627–9633 (2003).
- [6] S. C. Kuo, H. Z. Lee, J. P. Juang, Y. T. Lin, T. S. Wu, J. J. Cheng, D. Lednicer, K. D. Paull, C. M. Lin, E. Hamel, and K. H. Lee, *J. Med. Chem.*, **36**(9), 1146–1156 (1993).
- [7] L. Li, H. K. Wuang, S. C. Kuo, D. Lednicer, C. M. Lin, E. Hamel, and K. H. Lee, *J. Med. Chem.*, **37**(8), 1126–1135 (1994).
- [8] Y. Xia, Z. Y. Yang, S. L. Morris-Natschke, and K. H. Lee, *Curr. Med. Chem.*, **6**(3), 179–194 (1999).
- [9] Y. Xia, Z. Y. Yang, P. Xia, T. Hackel, E. Hamel, A. Mauger, J. H. Wu, and K. H. Lee, *J. Med. Chem.*, **44**(23), 3932–3936 (2001).
- [10] W. J. Wang, J. Y. Bai, and X. Y. Zhu, *Acta Pharm. Sinica.*, **28**(10), 738–743 (1993).
- [11] R. Y. Chen, H. L. Wang, and J. Zhou, *Heteroatom Chem.*, **5**(5), 497–501 (1994).
- [12] J. Han, X. N. Tan, and Y. Sun, *U.S. Patent* No. 4 826 830 (1989).
- [13] O. M. Friedman, E. Boger, V. Grubliauskas, and H. Sommer, *J. Med. Chem.*, **6**(1), 50–58 (1963).
- [14] T. S. Lin, P. H. Fischer, and W. H. Prusoff, *J. Med. Chem.*, **23**(11), 1235–1237 (1980).
- [15] R. Y. Chen and X. R. Chen, *Heteroatom Chem.*, **4**(6), 587–592 (1993).
- [16] R. Y. Chen and X. R. Chen, *Chem. J. Chinese U.*, **14**(7), 963–965 (1993).
- [17] M. J. Mphahlele, M. A. Fernandes, A. M. El-Nahas, H. Ottosson, S. M. Ndlovu, H. M. Sithole, B. S. Dladla, and D. De Waal, *J. Chem. Soc. Perkin Trans.*, **2**, **12**, 2159–2164 (2002).
- [18] M. P. Song, H. M. Liu, and M. C. Wang, *Experimental Organic Chemistry* (Zhengzhou Univ. Press, 2004), pp. 151–155.
- [19] O. M. Friedman and A. M. Seligman, *J. Am. Chem. Soc.*, **76**(3), 655–658 (1954).